Table 1 Endometrial hyperplasia patients treated with progestins
From: Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance
Case no. | Age (years) | Progestin dose | Treatment duration (months) | Diagnosis | Postprogestin findings |
|---|---|---|---|---|---|
Responders | |||||
1 | 25 | MA 40 mg qd | 5 | ACH | Progestin effects |
2 | 33 | MA 40 mg qd | 6 | ACH | Progestin effects, SM |
3 | 39 | MPA 20 mg qd | 3 | ASH | Progestin effects |
4 | 42 | Norethindrone acetate 1 mg qd | 5 | ACH | Progestin effects, SM |
5 | 45 | MPA 20 mg qd | 6 | ACH | Progestin effects |
6 | 25 | MA 40 mg qd | 3 | CH | Progestin effects, SM |
7 | 32 | MPA 10 mg qd (days 1–10) | 9 | CH | PE, Progestin effects, SM |
8 | 40 | Norethindrone acetate 1 mg qd | 2 | CH | Progestin effects |
9 | 42 | MPA 10 mg qd (days 1–10) | 6 | CH | PE, Progestin effects |
10 | 45 | MPA 20 mg qd | 4 | CH | Progestin effects |
11 | 48 | MPA 10 mg qd (days 1–10) | 3 | CH | Progestin effects |
12 | 50 | MPA 20 mg qd | 3 | CH | Progestin effects |
13 | 41 | MA 40 mg qd | 3 | SH | Progestin effects |
14 | 44 | MPA 20 mg qd | 2 | SH | Progestin effects, SM |
15 | 45 | MPA 10 mg qd (days 1–10) | 3 | SH | Progestin effects |
Non-responders | |||||
16 | 37 | MPA 20 mg qd | 6 | ACH | Focal ACH, progestin effects |
17 | 39 | MPA 20 mg qd | 3 | ACH | ACH, SM |
18 | 41 | MPA 20 mg qd | 2 | ACH | ACH, SM |
19 | 49 | MPA 10 mg qd | 3 | ACH | Focal ACH, PE, progestin effects |
20 | 24 | Norethindrone 1 mg qd | 3 | CH | focal CH, progestin effects |
21 | 27 | Progesterone 200 mg qd (4–6 months) | 12 | CH, | focal CH, progestin effects, SM |
22 | 39 | MPA 10 mg qd | 6 | CH | CH |
23 | 23 | MPA 10 mg qd | 6 | SH | SH, PE |
